Born 1953. Björn Dahlöf has extensive experience in cardiovascular research, pharmacology, drug development, and clinical trials (all phases) and has lectured in these areas internationally. Adviser to small and large pharmaceutical companies regarding drug development in all phases from preclinical development to larger lifecycle management studies after registration. Björn Dahlöf has initiated and led several major national and multinational mortality and morbidity studies that have had significance for guidelines in cardiovascular prevention and authored over 400 scientific publications.
Björn Dahlöf is medical doctor from the University of Gothenburg, internal medicine physician and associate professor at Sahlgrenska University Hospital, University of Gothenburg.
Member of the Board of PEXA AB, Goldwater Sweden AB. Chairman of the Board of BD Medical Consulting AB. Owner of BD Medical Consulting AB.
Björn Dahlöf is dependent of the company, the company management and independent of major shareholders as defined by the Swedish Code of Corporate Governance.